Other Events ·
At its Annual Meeting of Stockholders held on June 11, 2026, Vor Biopharma Inc. stockholders approved an amendment and…
VORVor Biopharma Inc.
At its Annual Meeting of Stockholders held on June 11, 2026, Vor Biopharma Inc. stockholders approved an amendment and restatement of the 2021 Equity Incentive Plan. The Amended 2021 Plan modifies the Evergreen Provision to calculate the annual 4% share reserve increase based on the sum of issued and outstanding common stock plus shares issuable upon exercise of pre-funded warrants. Additionally, the plan now provides for full vesting of unvested time-based awards upon an employee's death. Stockholders also elected Andrew Levin, M.D., Ph.D. and Fouad Namouni, M.D. as Class II Directors and ratified Ernst & Young LLP as the independent registered public accounting firm for the 2026 fiscal year. Vor Biopharma Inc. is a biotechnology company.